Novartis

Yuweitek is a scientific and technological enterprise specializing in the development and manufacture of advanced equipment for integrated circuit manufacturing. The company focuses on providing competitive products and technical solutions across various fields, including advanced packaging, compound semiconductors, and new displays. Yuweitek emphasizes the design and system integration of optical quality inspection systems for integrated circuits, offering a range of inspection products that include reticle, wafer, and pan-semiconductor inspections, as well as wafer measurement. Through its commitment to innovation and quality, Yuweitek aims to establish itself as a leading provider of integrated circuit equipment technology on a global scale.

Flare Therapeutics is a biotechnology company focused on developing small molecule medicines by exploring the biology of transcription factors. The company utilizes insights from its scientific founders to identify "switch sites," which are druggable regions that play a crucial role in regulating transcription factors and addressing disease-related mutations. Flare's innovative drug discovery efforts have led to a promising pipeline of drug programs targeting well-validated transcription factors, with an initial emphasis on precision oncology. The company's platform also holds potential for applications in neurology, rare genetic disorders, immunology, and inflammation, aiming to transform treatment approaches for various diseases.

Alladapt Immunotherapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics for food allergies. Founded in 2018 and based in Menlo Park, California, the company is advancing its lead program, ADP101, which aims to provide a broad-spectrum oral immunotherapy treatment. This innovative drug targets the mitigation, treatment, and prevention of food allergies caused by single or multiple proteins from a wide range of common allergens. Through its research and development efforts, Alladapt Immunotherapeutics seeks to enable healthcare providers to effectively address the challenges faced by patients with various food allergies.

Deciphex Limited, founded in 2017 and headquartered in Dublin, Ireland, specializes in developing digital pathology software applications. The company offers products such as Patholytix Preclinical, designed for preclinical and toxicologic pathology in pharmaceutical and clinical research organizations. Deciphex aims to transform the field of pathology by automating the visual examination of tissue samples, thereby optimizing workflows and allowing pathologists to concentrate on critical aspects of their work. As a High Potential Startup recognized by Enterprise Ireland, Deciphex is positioned to make significant advancements in the field of pathology through innovative technology.

Parrots Inc. is an assistive robotics and medical devices company focused on creating intelligent companions for individuals with mobility and communication challenges. Their socially assistive robots empower users and caregivers by enhancing interactions with the environment through features such as real-time communication, which utilizes an intuitive prediction system to facilitate faster dialogue. The robots are designed to be user-friendly, employing hands-free controls compatible with various ability switches, including eye-tracking and joystick options. Parrots' technology also incorporates advanced 360-degree computer vision, enabling users to navigate both indoor and outdoor spaces effectively. Additionally, the platform supports connectivity with smart-home devices and offers tools that maximize user independence while simultaneously alleviating the demands on caregivers. Through these innovations, Parrots aims to improve the quality of life for those with physical challenges by promoting autonomy and reducing caregiving burdens.

Klarah is a digital telehealth solution. They offer a network of specialist doctors for consultation and nurses to support patients. They also provide a dashboard with access to the medical history as well as virtual, near real-time updates on key health parameters. They offer services such as wound care, wellness checks, post-hospital care, and diabetes management.

Parrots Inc. is an assistive robotics and medical devices company focused on creating intelligent companions for individuals with mobility and communication challenges. Their socially assistive robots empower users and caregivers by enhancing interactions with the environment through features such as real-time communication, which utilizes an intuitive prediction system to facilitate faster dialogue. The robots are designed to be user-friendly, employing hands-free controls compatible with various ability switches, including eye-tracking and joystick options. Parrots' technology also incorporates advanced 360-degree computer vision, enabling users to navigate both indoor and outdoor spaces effectively. Additionally, the platform supports connectivity with smart-home devices and offers tools that maximize user independence while simultaneously alleviating the demands on caregivers. Through these innovations, Parrots aims to improve the quality of life for those with physical challenges by promoting autonomy and reducing caregiving burdens.

Holmusk Pte. Ltd. is a digital health and data analytics company focused on delivering real-world evidence for mental health and chronic diseases. Founded in 2015 and headquartered in Singapore, with additional offices in New York, Durham, London, and Cyberjaya, Holmusk develops an analytics platform that integrates scientific research, electronic health records, and behavioral health data to provide predictive algorithms and actionable insights for personalized medicine. The company offers solutions such as MindLinc, an electronic health record system that enhances longitudinal data for advanced analytics, and digital therapeutics that monitor and treat patients. Holmusk's platform supports various stakeholders in the healthcare ecosystem, including pharmaceutical companies, healthcare providers, payers, and regulators, facilitating informed care decisions and improving treatment outcomes for individuals managing behavioral health conditions. Through its innovative approach, Holmusk aims to advance data-driven, evidence-based care and aid in the research and development of new therapies.

Medtech Africa is an Africa-focused Medtech company headquartered in Nigeria, developing Connected Wearable Medical devices for Telemedicine care and remote patient health management. Medtech Connected Wearable medical device is a Wi-Fi enabled smart watch that monitors patients vitals in real-time and is linked to a telemedicine app that connects patients remotely to doctors across the world for personalized medical care.

Mekonos Inc. is a technology company based in San Francisco, California, focused on the design, development, and production of gene and cell therapies. Founded in 2017, Mekonos has developed a proprietary cell-engineering platform that utilizes scalable silicon technology and an integrated system-on-a-chip. This platform enables the creation of predictive models for drug discovery and development, as well as a silicon chip automated architecture for genome editing. The company's innovative MEMS technology allows for the precise control of individual nanoneedles to inject single cells in parallel, facilitating the industrialization of engineered therapies for genetic diseases, including cancers. By providing a reliable and reusable manufacturing system, Mekonos aims to enable healthcare providers to deliver a diverse range of therapeutic molecules across various primary cell types.

Xoma Corporation is a biotechnology company that specializes in the discovery and development of therapeutic candidates, focusing on monoclonal antibodies. The company has a diverse pipeline that includes proprietary product candidates such as X213, an allosteric inhibitor of prolactin, and XMetA, an insulin receptor-activating antibody aimed at treating Type 2 diabetes. Other notable programs target metastatic melanoma and renal cell carcinoma, as well as addressing conditions like primary hyperparathyroidism. Xoma also licenses its antibody discovery and development technologies to pharmaceutical and biotech firms, enhancing their clinical development efforts. The company collaborates with several prominent organizations, including Novartis and Takeda, to advance its research initiatives. Founded in 1981 and based in Emeryville, California, Xoma plays a significant role in supporting the biotech industry by acquiring future economic rights to pre-commercial therapeutic candidates, thereby providing critical funding for ongoing drug development efforts.

Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted protein degradation therapies.

Cellerys is a Zurich-based startup conducting research on a therapy to fight multiple sclerosis.

Aktis Oncology is a biotechnology company focused on developing targeted radiopharmaceuticals for the treatment of various solid tumor cancers. The company has created proprietary platforms that generate tumor-targeting agents optimized for alpha radiotherapy. These agents are engineered to achieve high penetration into tumors and prolonged residence time, allowing for effective tumor elimination while reducing side effects associated with treatment. Additionally, Aktis Oncology's innovative approach enables clinicians to visualize and confirm target engagement before administering therapeutic radioisotopes, enhancing the precision of cancer treatment.

Credence MedSystems, Inc. is a drug delivery and specialty pharmaceutical company based in Menlo Park, California, focused on enhancing the safety of injectable medications for patients and caregivers. The company develops innovative products, including the Companion Staked Needle Syringe, Companion Luer Syringe, and the Epiphany Safety Syringe system, which features a vacuum-triggered, auto-retractable mechanism for safer use. Credence MedSystems aims to simplify the commercialization process for pharmaceutical partners by integrating advanced safety features into existing drug delivery systems without necessitating significant changes to their manufacturing processes. This approach, termed "Innovation Without Change," allows for a more efficient path to market while ensuring that the delivery systems meet high standards of safety and efficacy. The company, formerly known as SafeShot Technologies, Inc., was established in 2011 and has formed a strategic collaboration with SCHOTT AG to further enhance its product offerings.

Aspen RxHealth is a Tampa, Florida-based company that operates an online platform designed to connect licensed pharmacists with patients seeking enhanced medication services. Through its app-based technology, Aspen RxHealth facilitates direct patient care by matching pharmacists with patients based on various social and clinical criteria, including language and medication regimens. The platform enables health plans and providers to easily link their patients to an on-demand community of pharmacists who can offer clinical services, ranging from comprehensive medication reviews to targeted interventions. By optimizing communication and streamlining the delivery of care, Aspen RxHealth aims to meet the diverse needs of patients effectively.

SomaLogic operates as a protein biomarker discovery and clinical diagnostics company. It offers SOMAmers (Slow-Offrate Modified Aptamers), which are modified nucleic acid-based protein-binding reagents that are specific for their cognate protein; and SOMAscan that provides protein detection and equipment. The company’s SOMAmer/SOMAscan technology enables to discover protein biomarker signatures; drug discovery and development; and clinical diagnostics. Its products have applications in the diagnostics of various diseases in oncology, neurology, cardiovascular and metabolic disease, and other diseases and conditions. SomaLogic was founded in 1999 and is headquartered in Boulder, Colorado.

Luc Therapeutics, founded in 2010 and based in Cambridge, Massachusetts, was a precision neuroscience company focused on developing novel allosteric modulators for ion channels aimed at improving neuronal firing regularity. The company specialized in creating subunit-selective NMDA receptor modulators, including NR2B negative allosteric modulators for depression and NR2B positive allosteric modulators to enhance cognitive function in schizophrenia. Additionally, it explored NR2A negative allosteric modulators to address disease progression and symptoms in Rett syndrome and other autism spectrum disorders. Luc Therapeutics was known for its innovative approach to restoring cognitive and motor functions in patients with serious neurological conditions by leveraging target specificity, patient selection, and drug optimization. In October 2017, Luc Therapeutics changed its name to Cadent Therapeutics.

Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

Mekonos Inc. is a technology company based in San Francisco, California, focused on the design, development, and production of gene and cell therapies. Founded in 2017, Mekonos has developed a proprietary cell-engineering platform that utilizes scalable silicon technology and an integrated system-on-a-chip. This platform enables the creation of predictive models for drug discovery and development, as well as a silicon chip automated architecture for genome editing. The company's innovative MEMS technology allows for the precise control of individual nanoneedles to inject single cells in parallel, facilitating the industrialization of engineered therapies for genetic diseases, including cancers. By providing a reliable and reusable manufacturing system, Mekonos aims to enable healthcare providers to deliver a diverse range of therapeutic molecules across various primary cell types.

Vedere Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on developing gene therapy products aimed at restoring functional vision for patients who have experienced vision loss due to Inherited Retinal Degenerations (IRDs) and other causes of vision impairment, both genetic and non-genetic. Unlike many ocular gene therapies that primarily slow the progression of vision loss, Vedere Bio seeks to restore lost vision, regardless of the patient's genetic background or stage of their condition. As of September 2020, Vedere Bio operates as a subsidiary of Novartis AG.

Molecular Partners AG is a clinical-stage biopharmaceutical company based in Schlieren, Switzerland, focused on developing innovative therapies for serious diseases. The company is advancing a new class of small protein therapeutics known as DARPin, exemplified by its lead candidate Abicipar, which is undergoing Phase III clinical trials for wet age-related macular degeneration and diabetic macular edema. Other candidates in development include MP0250, aimed at enhancing standard treatments for multiple myeloma, and MP0274, currently in Phase I trials for HER2-positive solid tumors. Additionally, MP0310 is being evaluated in Phase I trials for immuno-oncology applications, while MPO317 and Peptide-MHC are designed to activate immune responses within tumors. Molecular Partners collaborates with notable partners, including Allergan and Amgen, and is engaged in a program to develop anti-COVID-19 therapeutics in partnership with AGC Biologics. Founded in 2004, the company aims to significantly improve disease management through its cutting-edge therapeutic approaches.

Arkangel AI is a company focused on improving global health outcomes by utilizing an artificial intelligence platform designed to detect preventable diseases quickly and accurately. By achieving a detection accuracy of 90%, the platform generates results in seconds, making it a scalable and cost-effective solution for identifying diseases, especially in remote areas with limited healthcare infrastructure. Founded in 2019, Arkangel AI aims to reduce the death rate from viral diseases by combining scientific advancements with community knowledge, ensuring that equal health conditions are accessible to everyone worldwide. The company operates offices in Canada and Colombia.

Freenome, Inc., is an artificial intelligence (AI) genomics biotech company. The company develops and provides a medical arti?cial intelligence platform for early detection of cancer. It develops blood tests for early-cancer screening and treatment selection. The company also provides clinical research services. Freenome, Inc. was founded in 2014 and is based in South San Francisco, California.

Science 37, Inc. is a technology-driven clinical trial company focused on transforming clinical research through patient-centric models. It has developed NORA (Network Oriented Research Assistant), a cloud-based mobile research platform that facilitates communication between researchers and patients via videos, photographs, and surveys, enabling end-to-end networked clinical trial services. The company also offers the Science 37 Metasite, which enhances access to diverse patient populations for clinical studies, and the Science 37 Platform for decentralized clinical trials. By utilizing its virtual model, Science 37 has demonstrated faster enrollment and higher patient retention, reaching a broader and more representative patient demographic than traditional site-based research. The company serves a wide range of clients, including large pharmaceutical firms, biotechnology companies, universities, and startups. Since its incorporation in 2014, Science 37 has established itself as a leader in virtual clinical trials, leveraging an extensive network of telemedicine investigators and home-health nurses to conduct more decentralized interventional trials than any other organization.

AccessNow is all about sharing accessibility information around the world. Their goal is to map as many places as we possibly can, and They invite you to help us! A worldwide community, passionate about change, together we can empower each other to have access now.

Amblyotech, LLC is a company based in Atlanta, Georgia, focused on developing and commercializing electronic media therapies for the treatment of amblyopia and other ocular conditions in both adults and children. Founded in 2013, Amblyotech has created an innovative electronic media application that enhances visual acuity and aims to prevent reverse amblyopia. This application facilitates the establishment of 3D vision through the use of tablets, computers, and smartphones, offering a modern alternative to traditional treatments such as patching, atropine drops, and surgery. As of April 2020, Amblyotech operates as a subsidiary of Novartis AG.

The Medicines Company is a pharmaceutical firm dedicated to enhancing the treatment of critical care patients by providing innovative and cost-effective medicines to hospitals globally. The company's flagship product, Angiomax, is an anticoagulant used in patients undergoing coronary angioplasty, while Cleviprex is an injectable emulsion aimed at managing blood pressure in situations where oral therapy is unsuitable. In addition to these marketed products, The Medicines Company has two drugs in late-stage development: cangrelor, an investigational antiplatelet agent, and oritavancin, a semi-synthetic lipoglycopeptide antibiotic. The company is also advancing a serine protease inhibitor, CU2010, which is currently in early-stage development.

Immunitas Therapeutics, Inc. is focused on developing targeted therapies for cancer patients through innovative single-cell analyses. Founded in 2019 and based in Cambridge, Massachusetts, the company utilizes a single-cell sequencing platform to explore the biology of immune cells within human tumors. This approach allows Immunitas to identify novel drug targets rooted in human biology and create key biomarkers that assist in selecting patients who may benefit from their therapies. By translating laboratory findings into clinical applications, Immunitas aims to address longstanding challenges in oncology and improve treatment options for complex cancers. The company is advancing multiple programs toward early human studies, leveraging expertise in antibody discovery and engineering to develop effective treatments.

SiO2 Materials Science is a material sciences company specializing in the research, development, manufacturing, and marketing of engineered containers. The company provides innovative solutions for the pharmaceutical and biotechnology sectors, including inert containers designed for drug delivery systems and various diagnostic applications, such as glass blood collection tubes. Additionally, SiO2 offers custom packaging solutions and performance products tailored to meet the specific needs of clients in industries such as biotechnology, genomics, diagnostics, consumer products, and cosmetics. Established in 2011, SiO2 is headquartered in Auburn, Alabama, with an additional office located in Norristown, Pennsylvania.

Ayala Pharmaceuticals is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL02, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer, T-cell Acute Lymphoblastic Leukemia, Desmoid Tumors and Multiple Myeloma (in collaboration with Novartis).

Xiidra is a prescription eye drop solution designed to treat the signs and symptoms of dry eye disease.

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in San Diego, California, focused on developing innovative therapies for patients with significant unmet medical needs. The company is advancing a diverse pipeline that includes treatments for hematological malignancies and solid tumors, as well as liver-directed gene therapies aimed at rare diseases. Poseida is known for its proprietary gene engineering platforms, including the non-viral piggyBac DNA Modification System and the Cas-CLOVER site-specific gene editing system, which facilitate the creation of next-generation cell and gene therapeutics. Additionally, the company's portfolio encompasses CAR-T therapies for cancer and gene therapies targeting rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency and methylmalonic acidemia. Founded in 2014, Poseida Therapeutics is committed to addressing critical health challenges through its advanced therapeutic solutions.

TestCard Diagnostics Ltd, operating as TestCard.com, is a health technology company that specializes in at-home medical testing solutions. Founded in 2017 by Dr. Andrew Botham and Luke Heron, the company has developed an innovative pull-out urine test kit that integrates with a mobile application, allowing users to receive immediate results. The urinalysis system combines the precision of medical lab tests with mobile technology, enabling users to apply urine to a test strip embedded in a postcard and scan it with their smartphone to obtain clinical-grade results. TestCard's technology is designed for privacy and convenience, allowing individuals to diagnose and monitor common health conditions at home. The company has received approvals for its medical devices in 27 countries for detecting urinary tract infections and is expanding its product range to include tests for pregnancy, ovulation optimization, and diabetes management. Based in London, TestCard is at the forefront of the shift towards preventative healthcare solutions.

NIR is a biopharmaceutical company developing a suite of small-molecule antagonists targeting inappropriate inflammatory responses of the innate immune system via the NLRP3 pathway, which is believed to underlie a variety of serious diseases. The Company is developing chemically distinct systemic, gut-directed and CNS-penetrant drug candidates to address a breadth of indications triggered by NLRP3, including metabolic, fibrotic, autoimmune, autoinflammatory, and neurodegenerative diseases. IFM Tre was founded in 2017 and headquartered in Boston, Massachusetts.

Xealth Inc. operates a digital health prescribing platform designed to enhance the integration and management of digital health tools within healthcare systems. Founded in 2016 and based in Seattle, Washington, the platform allows clinicians to prescribe and monitor digital health solutions directly from electronic health records (EHR) workflows. This capability enables care teams to identify appropriate digital tools for patients, which can be sent to their smartphones or desktops for easy access. Additionally, Xealth supports patient education and offers services such as ride shares and food delivery. The platform facilitates monitoring of patient engagement, providing insights into the effectiveness of these digital interventions. Originally spun out of Providence St. Joseph Health in 2017, Xealth has attracted investments from various healthcare-focused entities, including McKesson Ventures and Novartis.

Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

CellforCure SASU, founded in 2010 and located in Les Ulis, France, is a contract development and manufacturing organization specializing in advanced therapy medicinal products. As a subsidiary of Novartis AG, the company focuses on manufacturing cell and gene-related products aimed at supporting hospitals and clinics. Through its expertise in cell therapy, CellforCure plays a significant role in the development and production of innovative therapeutic solutions in the healthcare industry.

Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate receptor positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.

CODA Biotherapeutics’ revolutionary chemogenetic platform aims to control the activity of cells to treat disease with chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable “switch” protein. Cells modified with the “switch” can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.

Mekonos Inc. is a technology company based in San Francisco, California, focused on the design, development, and production of gene and cell therapies. Founded in 2017, Mekonos has developed a proprietary cell-engineering platform that utilizes scalable silicon technology and an integrated system-on-a-chip. This platform enables the creation of predictive models for drug discovery and development, as well as a silicon chip automated architecture for genome editing. The company's innovative MEMS technology allows for the precise control of individual nanoneedles to inject single cells in parallel, facilitating the industrialization of engineered therapies for genetic diseases, including cancers. By providing a reliable and reusable manufacturing system, Mekonos aims to enable healthcare providers to deliver a diverse range of therapeutic molecules across various primary cell types.

Based in Dallas, Texas, AveXis is a clinic-ready, synthetic biology platform company. AveXis has, at its core, a desire to establish unique industry and research alliances which will bring innovative treatments to people with unmet medical needs. Our work in spinal muscular atrophy (SMA), a rare/orphan disease, is our first focus.

Rani Therapeutics, LLC, founded in 2012 and based in San Jose, California, specializes in developing oral biotherapeutics technologies for the delivery of large drug molecules, such as peptides, proteins, and antibodies. The company aims to provide a convenient alternative to traditional injection methods through its proprietary RaniPill capsule, which is designed to facilitate the oral administration of biologics. Rani Therapeutics offers a range of treatments targeting various health conditions, including TNF-alpha inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, the company develops therapies for multiple sclerosis, type II diabetes, obesity, and other inflammatory diseases using its innovative oral delivery system.

Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Advanced Accelerator Applications (AAA), is a European Pharmaceutical Group founded in 2002 by Italian academics as a spin-off of the “European Organization for Nuclear Research” (CERN), Geneva, Switzerland), to develop innovative diagnostic and therapeutic products. AAA’s main focus is in the field of Molecular Imaging and targeted, individualized therapy for the management of patients with serious conditions (Personalized Medicine). AAA is a European leader in the production and commercialization of PET (Positron Emission Tomography) radiopharmaceuticals. PET is a state-of-the-art diagnostic technique that is today mainly used in clinical oncology, cardiology and neurology. AAA also produces a broad range of SPECT products. AAA currently has 17 production and R&D facilities able to manufacture both diagnostics and therapeutic MNM products, and has over 300 employees in 11 countries (France, Italy, UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, United States and Canada).

Rani Therapeutics, LLC, founded in 2012 and based in San Jose, California, specializes in developing oral biotherapeutics technologies for the delivery of large drug molecules, such as peptides, proteins, and antibodies. The company aims to provide a convenient alternative to traditional injection methods through its proprietary RaniPill capsule, which is designed to facilitate the oral administration of biologics. Rani Therapeutics offers a range of treatments targeting various health conditions, including TNF-alpha inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, the company develops therapies for multiple sclerosis, type II diabetes, obesity, and other inflammatory diseases using its innovative oral delivery system.

Homology Medicines, Inc. is a genetic medicines company based in Bedford, Massachusetts, focused on improving the lives of patients with rare genetic diseases. The company employs a proprietary platform that utilizes human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to deliver genetic therapies in vivo, either through gene therapy or nuclease-free gene editing. This innovative approach allows for targeted treatment of various disease-relevant tissues, including the liver and central nervous system, through a single injection. Homology's lead product candidate, HMI-102, is currently in a Phase 1/2 clinical trial for treating phenylketonuria (PKU) in adults, while HMI-103 targets pediatric PKU patients, and HMI-202 is being developed for metachromatic leukodystrophy. Founded in 2015, Homology Medicines aims to address significant unmet medical needs by targeting the underlying causes of genetic disorders.

Anaeropharma Science, Inc. is a biopharmaceutical company based in Chiyoda, Japan, founded in 2004. The company specializes in the development of therapeutics aimed at treating solid cancers characterized by hypoxic environments. Utilizing its proprietary platform technology, which involves recombinant Bifidobacterium, Anaeropharma Science develops innovative solutions including APS001F for solid tumors, anticancer drugs in the immuno-oncology sector, and treatments for ischemia such as FGF2. The company's approach leverages genetically enhanced bacteria that thrive in the low-oxygen conditions typical of solid tumors, where they convert systemically administered pro-drugs into cytotoxic agents, thereby providing healthcare professionals with effective and safe therapeutic options for cancer and related hypoxic conditions.

Gamida Cell Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative cell therapies for blood cancers and serious blood diseases. The company's lead product candidate, omidubicel, utilizes expanded hematopoietic stem cells and differentiated immune cells, and is currently undergoing Phase 3 trials for high-risk hematologic malignancies, alongside Phase 1/2 trials for severe aplastic anemia. Additionally, Gamida Cell is advancing GDA-201, a natural killer cell-based immunotherapy, which is in Phase 1/2 studies for relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. Founded in 1998 and headquartered in Jerusalem, Israel, the company leverages a proprietary expansion platform that enhances the therapeutic potential of umbilical cord blood-derived cells and natural killer cells, aiming to address significant unmet clinical needs in the field of regenerative medicine.

ONL Therapeutics, Inc. is a biopharmaceutical company based in Ann Arbor, Michigan, focused on developing innovative therapies aimed at protecting vision by targeting photoreceptors. Established in 2006, the company specializes in creating photoreceptor protective agents that address the FAS apoptotic pathway, which is critical for preserving photoreceptor cells. With a growing market for retinal drugs exceeding $7 billion, ONL Therapeutics aims to overcome the limitations of existing treatments that do not target the initial neural component of vision loss. The company’s drug programs include small-molecule peptides designed to protect photoreceptors during vision-threatening conditions such as retinal detachment, ultimately enhancing patient outcomes and supporting successful surgical interventions.

Semma Therapeutics, Inc. is focused on developing innovative cell therapies for patients with Type 1 diabetes, who traditionally rely on insulin injections. Founded based on groundbreaking research by Professor Douglas Melton, the company has licensed a method to generate functional, insulin-producing beta cells in the laboratory. Semma Therapeutics aims to combine these proprietary cells with advanced devices to create a comprehensive therapy that can replace the missing beta cells without the need for immunosuppression. By striving to bring this transformative treatment to clinical application, Semma Therapeutics seeks to significantly enhance the lives of diabetes patients. Headquartered in Cambridge, Massachusetts, the company is a subsidiary of Vertex Pharmaceuticals and collaborates strategically with Defymed.

Encore Vision is a Fort Worth, Texas-based company specializing in the design and supply of eyewear products, including lenses, frames, and health technology equipment. The company is focused on developing innovative treatments for presbyopia, leveraging extensive mentorship from ophthalmologists and optometrists during its early stages. Encore Vision has made significant strides in securing intellectual property protection, boasting a robust patent portfolio that includes an issued U.S. patent, a notice of allowance for a second patent, and over 40 pending applications in the U.S. and internationally. The company has successfully completed in-vivo proof of concept studies in animal models and is progressing towards clinical studies in humans. Established in 2000, Encore Vision continues to advance its technology and products in the eyewear industry.

Ziarco, Inc. develops therapeutic agents for treating inflammatory and allergic diseases. The company was founded in 2012 and is based in Palo Alto, California.

Selexys Pharmaceuticals Corporation (Selexys) is a privately held company that is developing drugs to treat inflammatory and thrombotic diseases. They are targeting the underlying disease mechanism for these disorders. Their target is the adhesion of white blood cells to sites of inflammation mediated by the binding of two proteins, P-selectin and PSGL-1. The company is in preclinical development of humanized antibodies to P-selectin and PSGL-1 for the treatment of acute and chronic inflammatory and thrombotic disorders. Unregulated inflammatory processes play a major role in the harmful effects of multiple inflammatory disorders.

YourBio Health is focused on transforming the blood collection process by developing innovative products that simplify diagnostic testing for patients. The company's flagship technology, Touch Activated Phlebotomy (TAP), allows users to collect their own blood painlessly and easily through a single-step process. This advancement not only enhances patient autonomy but also facilitates access to critical diagnostic information, thereby improving healthcare delivery. The On Vivo platform further supports safe and efficient diagnostic testing, making it accessible to a wider audience. By integrating TAP technology with various diagnostic assays and analytical systems, YourBio Health aims to enhance the overall experience for both patients and clinicians in the healthcare landscape. Founded in 2007 and based in Medford, Massachusetts, the company is committed to advancing informed healthcare participation and outcomes.

Arcus Biosciences is a clinical-stage biopharmaceutical company based in Hayward, California, focused on developing innovative cancer therapies through insights in immunology. Founded in 2015 by experienced researchers from the biotechnology sector, the company is advancing a pipeline that includes several promising candidates. Notably, it is developing AB928, a dual A2a/A2b adenosine receptor antagonist, and Zimberelimab, an anti-PD-1 monoclonal antibody, both currently in clinical trials. Additionally, Arcus is working on AB154, an anti-TIGIT monoclonal antibody, and AB680, a small-molecule CD73 inhibitor, targeting various cancer types such as non-small cell lung cancer and pancreatic cancer. The company has established partnerships with organizations like Strata Oncology and AstraZeneca to enhance its research efforts and expand its clinical trials. By focusing on the ATP-adenosine pathway, which plays a crucial role in tumor immunosuppression, Arcus aims to create and optimize differentiated immuno-oncology therapies for patients.

IFM Therapeutics specializes in developing small molecule medicines that target the innate immune system to address complex challenges in treating inflammatory and autoimmune disorders, as well as cancer. The company collaborates with academic partners to leverage expertise in innate immunity alongside experienced drug discovery professionals. Its subsidiary, IFM Due, focuses on discovering and developing antagonists of the cGAS/STING pathway, aiming to treat conditions such as inflammation, neuroinflammation, autoimmunity, and cancer. Additionally, IFM Discovery, a newly established incubator within the company, is engaged in advancing a portfolio of genetically validated targets for next-generation therapies addressing inflammation, neuroinflammation, autoimmunity, and fibrosis. Through these initiatives, IFM Therapeutics seeks to enhance immune response and improve the quality of life for patients facing serious health challenges.

COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, specializing in cellular engineering and genome analysis through CRISPR-Cas9 technology. Founded in 2011, the company provides a gene editing platform that allows for targeted modifications in the genome. Its applications span various sectors, including human and animal therapeutics, agricultural biotechnology, and industrial biotechnology. Caribou's solutions facilitate the development of new disease models, enhance traits in plants, and support functional genomic screens. The company aims to advance both basic and applied biological research, leveraging its transformative capabilities to impact therapeutic development and bioproduction.

Pear Therapeutics, Inc. focuses on developing and delivering clinically validated software-based therapeutics aimed at treating behavioral health disorders, including psychiatric and neurologic conditions. The company creates digital therapies for severe conditions such as addiction, schizophrenia, pain, post-traumatic stress disorder, anxiety, depression, and chronic insomnia. Its key products include mobile digital therapies that incentivize patients for completing treatment modules, reSET for substance use disorder, reSET-O for opioid use disorder, and Somryst for insomnia. Additionally, Pear Therapeutics offers PearConnect, a comprehensive patient services center that provides support for patients throughout their treatment journey, connects healthcare providers to resources, and assists insurance companies with claims processing. Founded in 2013, Pear Therapeutics is headquartered in Boston, Massachusetts, with an additional office in San Francisco, California.

C4 is building on the knowledge with synthetic chemical compounds which it calls Degronimids. These compounds can be engineered and linked together to bind with many molecular targets that today’s drugs can’t bind with, Cohen said. The key insight, he said, is that the scientific founders have discovered a way to bind with select disease-causing proteins, and flag them as cellular trash, so that the ordinary proteasome garbage disposal system can get rid of them. Selecting the precise disease-related proteins to send to the trash is obviously critical, because any drug like this could cause serious side effects if it sent healthy proteins involved in normal cell processes to the trash. C4 Therapeutics is developing a new class of targeted protein degradation (TPD) therapeutics for the treatment of a broad range of diseases. Our Degronimid™ platform incorporates highly selective small molecule binders to target disease-causing proteins and facilitate their rapid destruction and clearance from the cell through the natural ubiquitin/proteasome system (UPS). Because of this distinctive mechanism, Degronimids are capable of hitting many more targets, including those previously thought to be undruggable, while reducing the potential for drug resistance. The broad applicability of Degronimids, and our chemical biology platform designed for accelerated validation, have the potential to make an unprecedented impact across many diseases through multiple industry collaborations as well as proprietary programs. The Company has received an exclusive worldwide license to the Degronimid platform and related IP from Dana-Farber.

Admune Therapeutics LLC, a clinical-stage biotech company, develops and delivers cytokine therapy drugs for the treatment of various cancers. It focuses on heterodimeric IL-15, an IL-15 agonist for various applications in cancer immunotherapy. The company is based in Danvers, Massachusetts. As of October 16, 2015, Admune Therapeutics LLC operates as a subsidiary of Novartis International AG.

Intellia Therapeutics is a genome editing company based in Cambridge, Massachusetts, focused on developing curative gene-editing treatments using the CRISPR/Cas9 technology. The company aims to address severe and life-threatening genetic diseases through both in vivo and ex vivo therapeutic approaches. Its pipeline includes programs targeting liver diseases such as transthyretin amyloidosis and hereditary angioedema, as well as conditions like primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Additionally, Intellia is developing engineered cell therapies for oncological and autoimmune diseases. The company has established collaborations with various entities, including leading pharmaceutical firms and research institutions, to enhance its research and development efforts. Founded in 2014, Intellia Therapeutics holds a comprehensive intellectual property platform for the therapeutic application of CRISPR technology, positioning it at the forefront of gene editing innovation.

Spinifex is backed by a syndicate of experienced life science investors including Novo Ventures, Canaan Partners, GBS Venture Partners, Brandon Capital Partners, Uniseed and UniQuest. Founded in 2005, Spinifex raised an initial AU$3.25 million in Series A fundraising and a total of AU$23.08 in Series B funding support the further development of EMA401. Spinifex raised a US$45 million in a Series C round led by Novo Ventures and including additional new investor Canaan Partners in 2014. Spinifex has a strong portfolio of intellectual property around its lead compound EMA01, follow on candidates and the use of AT2 receptor antagonists to treat both neuropathic & inflammatory pain and restore nerve conduction velocity deficits, including granted US, European, Japanese, Chinese, Australian and New Zealand patents.

Rani Therapeutics, LLC, founded in 2012 and based in San Jose, California, specializes in developing oral biotherapeutics technologies for the delivery of large drug molecules, such as peptides, proteins, and antibodies. The company aims to provide a convenient alternative to traditional injection methods through its proprietary RaniPill capsule, which is designed to facilitate the oral administration of biologics. Rani Therapeutics offers a range of treatments targeting various health conditions, including TNF-alpha inhibitors for inflammatory disorders, parathyroid hormone for osteoporosis, and human growth hormone for growth deficiencies. Additionally, the company develops therapies for multiple sclerosis, type II diabetes, obesity, and other inflammatory diseases using its innovative oral delivery system.

Aduro Biotech is a clinical-stage biopharmaceutical company based in Berkeley, California, established in 2000. The company specializes in the discovery, development, and commercialization of immunotherapy treatments aimed at leveraging the body's immune system to address challenging diseases. Aduro is advancing several product candidates, including ADU-S100, which is undergoing various clinical trials for the treatment of advanced solid tumors and melanoma in combination with established therapies. Additionally, Aduro is developing BION-1301, a monoclonal antibody targeting IgA nephropathy, currently in Phase I trials. The company also explores novel approaches to modulate immune responses through the stimulator of interferon genes pathway and is engaged in preclinical studies involving the CD27 co-stimulatory receptor. Aduro Biotech has established collaboration and licensing agreements with major pharmaceutical entities, including Novartis, Eli Lilly, and Merck.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, specializing in cellular engineering and genome analysis through CRISPR-Cas9 technology. Founded in 2011, the company provides a gene editing platform that allows for targeted modifications in the genome. Its applications span various sectors, including human and animal therapeutics, agricultural biotechnology, and industrial biotechnology. Caribou's solutions facilitate the development of new disease models, enhance traits in plants, and support functional genomic screens. The company aims to advance both basic and applied biological research, leveraging its transformative capabilities to impact therapeutic development and bioproduction.

BioLineRx Ltd. is a clinical-stage biopharmaceutical development company based in Modi’in, Israel, specializing in oncology. The company’s development pipeline includes several therapeutic candidates, such as BL-8040, a peptide aimed at treating solid tumors and hematological malignancies, as well as facilitating stem cell mobilization. Another candidate, AGI-134, is an immuno-oncology agent designed for solid tumors, while BL-5010 is a proprietary applicator intended for the non-surgical removal of skin lesions. BioLineRx has established collaborations with notable organizations, including a partnership with MSD in the cancer immunotherapy field, and agreements with MD Anderson Cancer Center and Genentech Inc. to explore combinations of BL-8040 with existing therapies in clinical studies for pancreatic and other solid tumors. Founded in 2003, BioLineRx is dedicated to addressing unmet medical needs and improving treatment options in oncology.

Intellia Therapeutics is a genome editing company based in Cambridge, Massachusetts, focused on developing curative gene-editing treatments using the CRISPR/Cas9 technology. The company aims to address severe and life-threatening genetic diseases through both in vivo and ex vivo therapeutic approaches. Its pipeline includes programs targeting liver diseases such as transthyretin amyloidosis and hereditary angioedema, as well as conditions like primary hyperoxaluria Type 1, alpha-1 antitrypsin deficiency, and Hemophilia B. Additionally, Intellia is developing engineered cell therapies for oncological and autoimmune diseases. The company has established collaborations with various entities, including leading pharmaceutical firms and research institutions, to enhance its research and development efforts. Founded in 2014, Intellia Therapeutics holds a comprehensive intellectual property platform for the therapeutic application of CRISPR technology, positioning it at the forefront of gene editing innovation.

Raze Therapeutics focuses on discovering and developing innovative oncology therapeutics that target essential metabolic pathways crucial for cancer growth and survival. The company is advancing a pipeline of treatments based on novel biological insights into how cancer cells reprogram their metabolism to support tumor development. By selectively targeting one-carbon metabolism through a proprietary platform, Raze aims to provide patients with quicker access to treatment and improve the chances of successful outcomes.

CoStim Pharmaceuticals Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing innovative antibody agents for cancer treatment. Founded in 2011, the company specializes in cancer immunotherapy, creating antibody drugs that target immunological checkpoint control mechanisms. By harnessing the body's immune response, CoStim aims to improve therapeutic options for patients with cancer.

Proteus Digital Health® is creating a new category of pharmaceuticals: Digital Medicines. Digital Medicines includes drugs that communicate when they’ve been taken, wearable sensors that capture physiologic response, applications that support patient self-care and physician decision making and data analytics to serve the needs of doctors and health systems. The goal of Digital Medicines is to empower patients and their families, enable physicians and health systems to more effectively manage risk and ensure that outcomes are reliably achieved.

Fougera Pharmaceuticals Inc. specializes in dermatology-focused specialty pharmaceuticals, primarily manufacturing topical products in the United States. The company has developed over 60 FDA-approved topical therapies in the last eight years, positioning it as a leader in the market. Fougera's expertise encompasses formulation development, clinical trials, manufacturing, distribution, and sales and marketing. Its product offerings cater to various healthcare providers, including hospitals, specialists, and general practitioners, as well as providing over-the-counter medicines for patients.

As a pioneering force in oncology, Genoptix regularly participates in industry conferences to share their findings, discuss emerging solutions, and create meaningful connections to advance the community.

Alcon is a prominent medical device and pharmaceuticals company specializing in eye care, founded in 1945 and headquartered in Geneva, Switzerland. It operates in two main segments: Vision Care and Surgical. The Vision Care segment includes a range of products such as contact lenses, lens care solutions, and ocular health items, with well-known brands like Dailies, Total1, and Air Optix, capturing a significant share of the U.S. contact lens market. The Surgical segment focuses on products used in ophthalmic surgeries, offering intraocular lenses, surgical equipment, and consumables, including the Centurion phacoemulsification device for cataract procedures and a diverse portfolio of intraocular lenses like PanOptix. Alcon's commitment to innovative solutions caters to the full spectrum of eye care needs, establishing it as a leading company in the global vision care industry.

Corthera Inc., previously known as BAS Medical, is a biopharmaceutical company focused on developing and commercializing therapies for acute care illnesses. The company's primary product candidate, relaxin, is derived from a naturally occurring polypeptide hormone and is currently undergoing a global phase 2/3 clinical trial aimed at treating acute decompensated heart failure. Corthera holds worldwide rights for the development and commercialization of relaxin, positioning it to address significant medical needs in this critical health area.

Nektar pioneered the development of novel forms of delivering therapeutics to the lungs.

Protez Pharmaceuticals is a medical research company that discovers, develops, and commercializes antibiotics for difficult-to-treat hospital-based infections. The company focuses on differentiated intravenous and oral small molecule antibiotics to address bacterial resistant, and chronic or recurrent infections. Protez Pharmaceuticals was founded by Christopher M. Cashman in 2003 and is headquartered in Malvern, Pennsylvania.

Covalys Biosciences AG engages in the development and production of tools for protein research. It also provides protein labeling products. The company was founded in 2002 and is based in Witterswil, Switzerland.

Chiron Corporation was an American biotechnology company based in Emeryville, California, founded in 1981 by William Rutter. Initially focused on ophthalmology, the company expanded its operations through various acquisitions and by 2005 reported revenues of approximately $1.9 billion. Chiron specialized in developing biopharmaceuticals, vaccines, and blood testing, with notable products including treatments for diabetic foot ulcers, lung infections, and cancer, as well as the manufacture of the MMR vaccine. In 2006, Chiron was acquired by Novartis Corporation.

Hexal is a German generic pharmaceutical manufacturer headquartered in Holzkirchen, Bavaria, and is part of the Sandoz Group. Established in 1986, Hexal specializes in the development, production, and marketing of a diverse range of pharmaceutical products, including patent-free medicines, over-the-counter (OTC) products, generics, biosimilars, and innovative biopharmaceuticals. The company focuses on bringing biosimilars to the German market, which are complex biological medicines derived from living organisms through advanced biotechnology techniques. These products, often based on recombinant proteins, represent a unique regulatory category distinct from traditional chemically synthesized drugs. With a workforce of over 4,000 employees across six sites in Germany, Hexal has established itself as a prominent player in the pharmaceutical industry since merging with Sandoz in 2006.

Lumenos is a pioneer in the Consumer-Driven Health Care industry, dedicated to transforming health care into a system that prioritizes individual health needs. The company offers innovative solutions that empower consumers through health accounts, including Health Reimbursement Accounts and Health Savings Accounts, along with access to information, services, and incentives. This approach aims to enhance consumer engagement in health-promoting behaviors, ultimately improving health outcomes. By focusing on the well-being of consumers, Lumenos seeks to create long-term cost efficiency for employers while fostering a health care environment that genuinely cares about health.

Roche is a global leader in pharmaceuticals and diagnostics, dedicated to improving healthcare through innovative solutions. The company, known for its research and development in oncology, virology, inflammation, and metabolic diseases, produces a wide range of medicines and in-vitro diagnostic tests. Its portfolio includes well-known cancer treatments such as Avastin, Herceptin, and MabThera, along with a comprehensive suite of diagnostic products and systems used in clinical laboratories and patient self-monitoring. Roche's diagnostics division plays a crucial role in integrated healthcare by providing tools for early disease detection and monitoring. Additionally, the Roche Venture Fund supports the growth of early-stage life science companies by investing in innovative technologies and research collaborations, focusing on areas such as biotechnology and molecular diagnostics. With a commitment to advancing healthcare, Roche operates globally, with a strong presence in Europe, North America, and Asia, and actively collaborates with leading venture funds to drive innovation in the industry.

Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform.

Lumenos is a pioneer in the Consumer-Driven Health Care industry, dedicated to transforming health care into a system that prioritizes individual health needs. The company offers innovative solutions that empower consumers through health accounts, including Health Reimbursement Accounts and Health Savings Accounts, along with access to information, services, and incentives. This approach aims to enhance consumer engagement in health-promoting behaviors, ultimately improving health outcomes. By focusing on the well-being of consumers, Lumenos seeks to create long-term cost efficiency for employers while fostering a health care environment that genuinely cares about health.

Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform.